Pharma News and Healthcare Business Insights
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
We’re the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations. Equip your business with the right intelligence tools to ensure you are kept up-to-date with the latest news and are well informed of key regulatory changes affecting your organization.
Get the latest biotech and pharma news from Scrip with best-in-class proprietary data from a global team of analysts. From licensing, to clinical trials, to competitor activity, Scrip is essential for anyone making commercial decisions in the pharmaceutical industry. Find out more about SCRIP’s Global Pharma News service.
Stay compliant with Pink sheet and enhance your business opportunities with unparalleled access to global pharmaceutical regulatory expertise. From licensing, to clinical trials, to competitor activity - you’ll stay up to date on developments in your market. Find out more about Pink Sheet with in-depth insight into Pharmaceutical Regulatory Affairs.
Get key insights into the latest pharmaceutical and healthcare trends across the biopharma, Medtech and diagnostics industries from In Vivo. Get a window into what the key players in the biopharma, medtech, and diagnostics industries are thinking. Find out more about In Vivo and its key insights into the Latest Pharmaceutical Trends.
Medtech Insight provides analysis and diagnostic developments in medical technology news from opinion leaders across the globe. Discover the latest in innovation, investment trends and shifts in industry dynamics, gaining insight into the breakthrough technologies that will impact the industry. Find out more about Medtech Insights and the latest Medical Technology News.
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Click to read more...
US payers are expecting biosimilar manufacturers to offer significant discounts versus the originator price – as much as 40%-50% lower . Click to read more...
Biosimilar sponsors are 0-3 so far in attempts to win US FDA approval for copies of Amgen’s pegfilgrastim (Neulasta). Click to read more...
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies. Click to read more...
The pharmaceutical industry may have pioneered some great science, but when it comes to digital health it has been behind the curve. As patients and payers open up to the idea pharma. Click to read more...
Pharma Pipeline 2017:
The Pharmaceutical and Biotech industries’ R&D performance can be measured in a number of ways. Here is a look at its worldwide output of novel drug launches for 2016 and total pipeline size in 2017. Click to read more...
Orphan Drug Pricing:
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs. Click to read more...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: